Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52

Inhibition of glycolysis process has been an attractive approach for cancer treatment due to the evidence that tumor cells are more dependent on glycolysis rather than oxidative phosphorylation pathway. Preliminary evidence shows that inhibition of phosphoglycerate kinase 1 (PGK1) kinase activity wo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Acta pharmacologica Sinica 2021-04, Vol.42 (4), p.633-640
Hauptverfasser:	Wang, Wen-liang, Jiang, Zong-ru, Hu, Chen, Chen, Cheng, Hu, Zhen-quan, Wang, Ao-li, Wang, Li, Liu, Jing, Wang, Wen-chao, Liu, Qing-song
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - analogs & derivatives Adenine - pharmacology Adenine - therapeutic use Animals Apoptosis - drug effects Biomedical and Life Sciences Biomedicine Cell cycle Cell Line, Tumor Cell proliferation Cell Proliferation - drug effects Drug Screening Assays, Antitumor Enzyme inhibitors Epithelial-Mesenchymal Transition - drug effects Female Glioma Glioma - drug therapy Glioma - enzymology Glioma cells Glucose metabolism Glycolysis High-throughput screening Humans Immunology Internal Medicine Kinases Medical Microbiology Mice Mice, Nude Oral administration Oxidative phosphorylation Pharmacology/Toxicology Phosphoglycerate kinase Phosphoglycerate Kinase - antagonists & inhibitors Phosphoglycerate kinase 1 Phosphorylation Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Pyruvic acid Therapeutic targets Tricarboxylic acid cycle Tumor cells Vaccine Warburg Effect, Oncologic - drug effects Xenograft Model Antitumor Assays Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!